about
Natural killer cells control a T-helper 1 response in patients with Behçet's disease.Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5.Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis.The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosisPeriostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis.A peptide derived from endostatin ameliorates organ fibrosis.Role of endostatin in fibroproliferative disorders.-as a candidate for anti-fibrosis therapy-.Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients.Anti-inflammatory effect of collagen tripeptide in atopic dermatitis.Cerebellar ataxia-dominant phenotype in patients with ERCC4 mutations.Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.Transient receptor potential cation 3 channel regulates melanoma proliferation and migration.Genetic background and therapeutic response in generalized pustular psoriasis patients treated with granulocyte and monocyte adsorption apheresis.Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-β signaling.Anaphylaxis due to carmine-containing foods induced by epicutaneous sensitization to red eye-liner.A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases.Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment.Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome.Clinical features of Birt-Hogg-Dubé syndrome: A Japanese case with pulmonary cysts, fibrofolliculomas and renal cell carcinoma.Case of widespread purpura due to emboli of Candida parapsilosis.GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behçet's disease.Downregulated Caveolin-1 expression in circulating monocytes may contribute to the pathogenesis of psoriasisInterleukin-18 is elevated in the horny layer in patients with atopic dermatitis and is associated with Staphylococcus aureus colonizationAssociation of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitisOral administration of collagen tripeptide improves dryness and pruritus in the acetone-induced dry skin modelAnalysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patientsSerum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosisDecreased Expression of Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in MiceDevelopment of mucous membrane pemphigoid with antibodies to the β3 subunit of laminin 332 and bronchiolitis obliterans in a patient with chronic graft-versus-host diseasePustulosis palmaris et plantaris successfully treated with leukotriene antagonistPeriostin levels correlate with disease severity and chronicity in patients with atopic dermatitisClinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositisVitamin D is no substitute for the sunCase of intractable scalp pustulosis with alopecia diagnosed with amicrobial pustulosis of the foldsVaried responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patientsLong-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study
P50
Q34027448-36494B89-919E-454C-BFD7-0F8C5B4E1644Q34367785-6181B751-431B-45BB-8BBC-D65FBB6454ECQ34382756-A021488F-A22C-472D-843A-26B6A94701F8Q35097280-29816112-D97A-4CB4-B9CC-FB241CEB5AFBQ36326780-370FE14E-5A7C-4722-B280-E266CF6C2A4AQ36691823-2331FCE8-F835-4DCC-9152-8E81A52753CEQ37340061-B0F83DBA-F46B-458B-9607-856E152937C0Q38175824-D4C48D95-C417-4480-BADE-C940904B7969Q41051764-B955D28C-E514-4B35-886E-4ED200F6EF99Q42512779-855995C3-B450-4147-A294-9A0F89F0D47BQ47669867-841D2207-8813-4540-B4B8-A77C6933A087Q48102552-8245F1AD-A869-40D6-8842-EBA0884AA298Q48144281-79988E85-7EBE-49F4-AB53-B474C3696BA8Q48296840-A2081FAB-7D2F-43A2-953E-B40CD524A0E4Q48361608-3E9EE94F-1AF5-465E-A0D4-F3C023974174Q49584655-A1212C57-956F-4FFF-AF7C-CEF3D6922018Q50056736-22A28AAC-F24C-4200-836A-141769467D89Q50240225-E1360D24-4E8D-4912-862F-D4721754D571Q51051272-4E8E43BB-9B25-4613-9113-FF24D423857FQ52593722-8042BE47-1197-47A9-B287-DF24840CF6B7Q52886990-7605B5FC-674D-4D50-92AD-B5C93E7C0E0AQ53531762-E5F36129-AF26-4A31-B240-2D14FAB4A81DQ54652598-ECA22D40-B6B3-48AF-B0B8-D665B3034BECQ54733171-3E3D95FB-9DBB-442F-9D6D-D80CAE8B13B5Q55385001-432E95C7-53FB-4EBE-B2B0-7B955BB1CEDAQ60908477-C9C330B0-C6BC-4862-91D5-18E18482644CQ82502935-CD0565C0-88E9-4E60-B923-3C0AB714C9BDQ82833947-69525ACE-17A7-4ACE-9D18-02B72E6A8BA8Q83628828-94C16B21-5CEB-4868-9826-329BE905BB5AQ84869144-9941CB5D-9A27-4395-94A1-4061CBB81C96Q85315860-2CE58B5D-A51A-4CF0-A9BE-57AF83F11A60Q85511602-5E5C3016-7720-44BE-8698-207DE020FABFQ85729261-2F080CFF-5C0E-496F-B275-ED543A1C2F12Q86709938-4DF4AA27-A19E-444E-B502-64CAB1280FE3Q87409533-A8F97683-C2A0-494B-8DAE-2AFF0FFFC4CFQ89903953-ED7490EF-6419-4F5B-81A4-FFE534D1E501Q91124111-3CB97098-4241-4683-AE2F-C518B9B6A4BFQ91132607-6816AA46-E016-4D8C-BBC1-3FACF57B9CFCQ91344404-25293EC2-519C-450E-80A5-5F50B87EBB23Q91801330-E7027AAF-50FB-47B2-8818-214859F49405
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yukie Yamaguchi
@ast
Yukie Yamaguchi
@en
Yukie Yamaguchi
@es
Yukie Yamaguchi
@nl
Yukie Yamaguchi
@sl
type
label
Yukie Yamaguchi
@ast
Yukie Yamaguchi
@en
Yukie Yamaguchi
@es
Yukie Yamaguchi
@nl
Yukie Yamaguchi
@sl
prefLabel
Yukie Yamaguchi
@ast
Yukie Yamaguchi
@en
Yukie Yamaguchi
@es
Yukie Yamaguchi
@nl
Yukie Yamaguchi
@sl
P106
P1153
36700599500
P21
P31
P496
0000-0002-0297-6627
P569
2000-01-01T00:00:00Z